Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease

Thrombosis Research

Volumn 150, Issue , 2017, Pages 90-95

  Verdoia, Monica ^a   Pergolini, Patrizia ^a   Rolla, Roberta ^a   Nardin, Matteo ^a,b   Schaffer, Alon ^a   Barbieri, Lucia ^a,c   Daffara, Veronica ^a   Marino, Paolo ^a   Bellomo, Giorgio ^a   Suryapranata, Harry ^d   De Luca, Giuseppe ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b SPEDALI CIVILI   (Italy)

^c SANT'ANDREA HOSPITAL   (Italy)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coronary artery disease; Platelet aggregation; Statins; Vitamin D

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARACHIDONIC ACID; ATORVASTATIN; CALCIUM; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; PEPTIDE; ROSUVASTATIN; THROMBIN ACTIVATING PEPTIDE; UNCLASSIFIED DRUG; VITAMIN D; ANTITHROMBOCYTIC AGENT; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; SMOKING; THROMBOCYTE FUNCTION; VITAMIN BLOOD LEVEL; BLOOD; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; THROMBOCYTE; THROMBOCYTE AGGREGATION;

AGED; ATORVASTATIN CALCIUM; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; ROSUVASTATIN CALCIUM; SIMVASTATIN; VITAMIN D;

EID: 85008411874     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.12.019     Document Type: Article

References (46)

1. [1] De Luca, G., Biondi-Zoccai, G., Marino, P., Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann. Emerg. Med. 52:6 (2008), 665–676.
2. [2] De Luca, G., Marino, P., Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Am. J. Emerg. Med. 27:6 (2009), 683–690.
3. [3] Verdoia, M., Schaffer, A., Suryapranata, H., De Luca, G., Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials. Nutr. Metab. Cardiovasc. Dis. 25:1 (2015), 9–23.
4. [4] Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:9493 (2005), 1267–1278.
5. [5] Ballantyne, C.M., Low-density lipoproteins and risk for coronary artery disease. Am. J. Cardiol. 82 (1998), 3Q–12Q.
6. [6] Nissen, S.E., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., Davignon, J., Erbel, R., Fruchart, J.C., Tardif, J.C., Schoenhagen, P., Crowe, T., Cain, V., Wolski, K., Goormastic, M., Tuzcu, E.M., ASTEROID Investigators, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:13 (2006), 1556–1565.
7. [7] Law, M.R., Wald, N.J., Rudnicka, A.R., Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 326, 2003, 1423.
8. [8] Wang, C.Y., Liu, P.Y., Liao, J.K., Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 14 (2008), 37–44.
9. [9] Davignon, J., Beneficial cardiovascular pleiotropic effects of statins. Circulation 109:23 Suppl 1 (2004), III39–III43.
10. [10] Pera, Ł., Sygitowicz, G., Białek, S., Łukaszkiewicz, J., Sitkiewicz, D., Vitamin D and statins: action in preventing cardiovascular events. Kardiol. Pol. 70:12 (2012), 1296–1298.
11. [11] Perez-Castrillon, J.L., Vega, G., Abad, L., et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am. J. Cardiol. 99 (2007), 903–905.
12. [12] Kunadian, V., Ford, G.A., Bawamia, B., Qiu, W., Manson, J.E., Vitamin D deficiency and coronary artery disease: a review of the evidence. Am. Heart J. 167:3 (2014), 283–291.
13. [13] Lamendola, C.A., Ariel, D., Feldman, D., Reaven, G.M., Relations between obesity, insulin resistance, and 25-hydroxyvitamin D. Am. J. Clin. Nutr. 95 (2012), 1055–1105.
14. [14] Forman, J.P., Bischoff-Ferrari, H.A., Willett, W.C., Stampfer, M.J., Curhan, G.C., Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 46 (2005), 676–682.
15. [15] Giovannucci, E., Liu, Y., Hollis, B.W., Rimm, E.B., 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168 (2008), 1174–1180.
16. [16] Kane, L., Moore, K., Lütjohann, D., Bikle, D., Schwartz, J.B., Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships. J. Clin. Endocrinol. Metab. 98:11 (2013), 4400–4409.
17. [17] Sathyapalan, T., Shepherd, J., Atkin, S.L., Kilpatrick, E.S., The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes. Metab. 15:8 (2013), 767–769.
18. [18] Rejnmark, L., Vestergaard, P., Heickendorff, L., Mosekilde, L., Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomized, controlled trial. Int. J. Endocrinol. 9 (2010), 1–6.
19. [19] Choudhry, N.K., Levin, R., Winkelmayer, W.C., Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart 93:8 (2007), 945–951.
20. [20] De Luca, G., Secco, G.G., Santagostino, M., Venegoni, L., Iorio, S., Cassetti, E., Verdoia, M., Coppo, L., Di Mario, C., Bellomo, G., Marino, P., Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr. Metab. Cardiovasc. Dis. 22 (2012), 426–433.
21. [21] Holick, M.F., Vitamin D deficiency. N. Engl. J. Med. 357:3 (2007), 266–281.
22. [22] Verdoia, M., Pergolini, P., Camaro, C., Restifo, M., Rolla, R., Schaffer, A., Di Giovine, G., Marino, P., Bellomo, G., Suryapranata, H., De Luca, G., Novara Atherosclerosis Study Group (NAS), PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul. Fibrinolysis 24:4 (2013), 411–418.
23. [23] De Luca, G., Smit, J.J., Ernst, N., Suryapranata, H., Ottervanger, J.P., Hoorntje, J.C., Dambrink, J.H., Gosslink, A.T., de Boer, M.J., van't Hof, A.W., Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb. Haemost. 93 (2005), 820–823.
24. [24] De Luca, G., Cassetti, E., Verdoia, M., Marino, P., Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb. Haemost. 102:3 (2009), 428–436.
25. [25] De Luca, G., Navarese, E.P., Suryapranata, H., A meta-analytic overview of thrombectomy during primary angioplasty. Int. J. Cardiol. 166:3 (2013), 606–612.
26. [26] Nichols, M., Townsend, N., Scarborough, P., Rayner, M., Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J., 35, 2014, 2950.
27. [27] Lee, J.H., O'Keefe, J.H., Bell, D., Hensrud, D.D., Holick, M.F., Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?. J. Am. Coll. Cardiol. 52:24 (2008), 1949–1956.
28. [28] Chitalia, N., Ismail, T., Tooth, L., Boa, F., Hampson, G., Goldsmith, D., Kaski, J.C., Banerjee, D., Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One, 9(3), 2014, e91363.
29. [29] Verdoia, M., Schaffer, A., Sartori, C., Barbieri, L., Cassetti, E., Marino, P., Galasso, G., De Luca, G., Vitamin D deficiency is independently associated with the extent of coronary artery disease. Eur. J. Clin. Investig. 44:7 (2014), 634–642.
30. [30] van Etten, E., Mathieu, C., Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 97 (2005), 93–101.
31. [31] Silvagno, F., De Vivo, E., Attanasio, A., Gallo, V., Mazzucco, G., Pescarmona, G., Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS One, 5, 2010, e8670.
32. [32] Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., Packard, C.J., West of Scotland Coronary Prevention Study Group, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler. Suppl. 5:3 (2004), 91–97.
33. [33] Lewis, S.J., Moye, L.A., Sacks, F.M., Johnstone, D.E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S.P., Grant, J., Davis, B.R., Pfeffer, M.A., Braunwald, E., Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. Ann. Intern. Med. 129:9 (1998), 681–689.
34. [34] Hausenloy, D.J., Yellon, D.M., Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad. Med. J. 84:997 (2008 Nov), 590–598.
35. [35] Liberopoulos, E.N., Makariou, S.E., Moutzouri, E., Kostapanos, M.S., Challa, A., Elisaf, M., Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J. Cardiovasc. Pharmacol. Ther. 18:3 (2013 May), 229–233.
36. [36] Ware, W.R., The JUPITER lipid lowering trial and vitamin D. Dermato-Endocrin 2 (2010), 50–54.
37. [37] Ertugrul, D.T., Yavuz, B., Cil, H., Ata, N., Akin, K.O., Kucukazman, M., Yalcin, A.A., Dal, K., Yavuz, B.B., Tutal, E., STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc. Ther. 29:2 (2011), 146–152.
38. [38] Staal, A., Frith, J.C., French, M.H., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 18 (2003), 88–96.
39. [39] Thabit, A., Alhifany, A., Alsheikh, R., Namnqani, S., Al-Mohammadi, A., Elmorsy, S., Qari, M., Ardawi, M., Effect of simvastatin and atorvastatin on serum vitamin D and bone mineral density in hypercholesterolemic patients: a cross-sectional study. J. Osteoporos., 2014, 2014, 468397.
40. [40] Anagnostis, P., Adamidou, F., Slavakis, A., Polyzos, S.A., Selalmatzidou, D., Panagiotou, A., Athyros, V.G., Karagiannis, A., Kita, M., Comparative effect of atorvastatin and rosuvastatin on 25-hydroxy-vitamin D levels in non-diabetic patients with dyslipidaemia: a prospective randomized open-label pilot study. Open Cardiovasc. Med. J. 8 (2014), 55–60.
41. [41] Schwartz, J.B., Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin. Pharmacol. Ther. 85 (2009), 198–203.
42. [42] Xu, Y., Hashizume, T., Shuhart, M.C., et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol. Pharmacol. 69 (2006), 56–65.
43. [43] Grimes, D.S., Are statins analogues of vitamin D. Lancet 368 (2006), 83–86.
44. [44] Bhattacharyya, S., Bhattacharyya, K., Maitra, A., Possible mechanisms of interaction between statins and vitamin D. QJM 105:5 (2012), 487–491.
45. [45] Verdoia M, Pergolini P, Rolla R, Sartori C, Nardin M, Barbieri L, Schaffer A, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Platelets 2016; Early Online 1–7, doi: 10.3109/09537104.2016.1149159.
46. [46] Siller-Matula, J.M., Gruber, C., Francesconi, M., Dechant, C., Jilma, B., Delle-Karth, G., Grohs, K., Podczeck-Schweighofer, A., Christ, G., The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin. Sci. (Lond.) 128 (2015), 121–130.